Vladimir Gabay, MD
Internal Medicine · Forest Hills, NYNPI 1558458356
Payments from drug & device makers
Across 282 payments — averaging $19.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$814
- Amgen$451
- Amarin Pharma, Inc.$407
- Merck$276
- Novo Nordisk$259
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,557100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 66 | $1,159 |
| AstraZeneca | 40 | $814 |
| Amgen(2 entities) | 23 | $451 |
| Amarin Pharma, Inc. | 18 | $407 |
| Merck | 19 | $276 |
| Novo Nordisk | 14 | $259 |
| Pfizer | 13 | $249 |
| Kowa Pharmaceuticals America, Inc. | 8 | $196 |
| GSK | 11 | $192 |
| Aimmune Therapeutics, Inc. | 5 | $189 |
| Boehringer Ingelheim | 7 | $149 |
| Lilly USA, LLC | 8 | $142 |
| Incyte Corporation | 7 | $137 |
| Ardelyx, Inc. | 4 | $96 |
| Exact Sciences | 3 | $90 |
| Daiichi Sankyo Inc. | 4 | $84 |
| Biohaven Pharmaceuticals, Inc. | 3 | $83 |
| Cequr Corporation | 1 | $77 |
| Johnson & Johnson | 4 | $68 |
| Nestle Healthcare Nutrition Inc. | 3 | $62 |
| Sanofi | 2 | $55 |
| Axsome Therapeutics, Inc. | 2 | $55 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $44 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $36 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $26 |
| Amneal Pharmaceuticals LLC | 1 | $22 |
| Astellas Pharma US Inc | 1 | $18 |
| Impel Pharmaceuticals Inc. | 1 | $17 |
| Sebela Pharmaceuticals Inc. | 1 | $17 |
| Scilex Pharmaceuticals Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $14 |
| Bausch Health US, LLC | 1 | $14 |
How this compares
$5,569 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 145 | $251,478 |
| Diclofenac Sodium | 287 | $153,500 |
| OzempicSemaglutide | 122 | $126,700 |
| Dihydroergotamine Mesylate | 77 | $120,750 |
| EliquisApixaban | 107 | $114,062 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 72 | $108,207 |
| JanuviaSitagliptin Phosphate | 120 | $106,137 |
| LinzessLinaclotide | 170 | $99,147 |
| Nurtec OdtRimegepant Sulfate | 53 | $88,545 |
| JubliaEfinaconazole | 83 | $84,523 |
| XareltoRivaroxaban | 90 | $71,519 |
| VascepaIcosapent Ethyl | 168 | $71,361 |
| Dupixent PenDupilumab | 19 | $66,186 |
| FarxigaDapagliflozin Propanediol | 67 | $63,781 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 86 | $59,819 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Ubrelvy, Restasis, Creon, Namzaric | $1,159 | $263,888362 claims |
| Aimmune Therapeutics, Inc.Zenpep | $189 | $251,478145 claims |
| PfizerEliquis, Nurtec Odt, Effexor Xr | $249 | $246,930189 claims |
| MerckJanuvia, Janumet | $276 | $132,079180 claims |
| Novo NordiskOzempic | $259 | $126,700122 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Nexium | $814 | $120,274178 claims |
| Boehringer IngelheimJardiance, Tradjenta | $149 | $83,13797 claims |
| Johnson & JohnsonXarelto | $68 | $71,51990 claims |
| GSKTrelegy Ellipta | $192 | $59,81986 claims |
| Ardelyx, Inc.Ibsrela | $96 | $59,27736 claims |
| Lilly USA, LLCMounjaro, Trulicity | $142 | $58,83059 claims |
| Astellas Pharma US IncMyrbetriq | $18 | $57,729115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Forest Hills
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.